| Study Number |
Title |
| 12-1157 |
Topoisomerase 2A (TOPO2A) Amplification/Overexpression and Other Predictive/Prognostic Markers in Women with Endometrial Cancer
|
| 12-1419 |
GOG 277: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
|
| 12-1650 |
GOG 275: A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day
Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
|
| 12-1767 |
Endometrial Cancer Survivorship: A Qualitative Approach to Understanding Healthy Lifestyle Change in African American Endometrial Cancer Survivors and Their Support Network
|
| 12-1950 |
Endometrial Cancer Survivorship: Reducing Obesity and Reducing Disparity
|
| 12-2015 |
GOG 231D: A Phase II Evaluation of MLN8237 (NSC #747888, IND #113149) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
|
| 09-161-B |
GOG 258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
|
| 10-386-A |
GOG 261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
|
| 10-627-A |
GOG 8013: Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression As Well As Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated with Anthracycline-Based Therapy
|
| 10-635-A |
GOG 130F: A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
|
Bone